 Nektar Therapeutics Inc NASDAQ: NKTR has entered into a new oncology clinical collaboration with Merck KGaA OTC: MKGAF and Pfizer Inc NYSE: PFE to evaluate the maintenance regimen of NKTR-255 in combination with avelumab in bladder cancer study. The Phase 2 JAVELIN Bladder Medley study will include locally advanced or metastatic urothelial carcinoma UC patients. 